跳至主要内容
临床试验/NCT05044533
NCT05044533已完成不适用

Evaluating QUAlity of Life of AF Patients Following a Bleed (EQUAL-AF)

Bristol-Myers Squibb1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2021年5月31日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
50
试验地点
1
主要终点
Distribution of characteristics of AF participants: Quality of life (QoL) data

研究概览

简要总结

The purpose of this observational study is to identify participants with both minor and major bleeds as a result of anticoagulant treatment for AF and evaluating their QoL through both primary and secondary care settings.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Adult patients (>= 18 years old)
  • •Patients who can understand all study information and literature to provide fully informed consent
  • •Atrial fibrillation (AF) as the primary diagnosis
  • •Having a major or minor bleed up to a maximum of 30 days prior to point of enrolment
  • •Receiving oral anticoagulation therapy for AF

排除标准

  • •Pregnant women
  • •Patients with active cancer
  • •Patients unable to consent for themselves
  • •Patient on concomitant antiplatelet therapy

结局指标

主要结局

Distribution of characteristics of AF participants: Quality of life (QoL) data

时间窗: Up to 90 days

Distribution of characteristics of AF participants: Impact of the anticoagulation treatment

时间窗: Up to 90 days

次要结局

  • Distribution of outcomes of AF participants: Timing of bleeding occurrence(Up to 90 days)
  • Distribution of outcomes of AF participants: Nature of the bleed(Up to 90 days)
  • Distribution of outcomes of AF participants: Documented cause of bleed(Up to 90 days)
  • Distribution of outcomes of AF participants: Current Bleeding treatment(Up to 90 days)
  • Distribution of outcomes of AF participants: Location of bleed(Up to 90 days)

研究者

发起方
Bristol-Myers Squibb
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验